This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Steták, A. Articles by Ullrich, A. Search for Related Content PubMed PubMed Citation Articles by Steták, A. Articles by Ullrich, A.

Nuclear Translocation of the Tumor Marker Pyruvate Kinase M2 Induces Programmed Cell Death

¹ Department of Molecular Biology, Max-Planck-Institute for Biochemistry, Martinsried, Germany; ² Peptide Biochemistry Research Group of Hungarian Academy of Sciences; ³ Department of Medical Chemistry, Semmelweis University; and ⁴ Institute of Enzymology, Biological Research Center, Hungarian Academy of Sciences, Budapest, Hungary

Requests for reprints: Attila Steták, Institute of Zoology, University of Zürich, Winterthurerstrasse 190, 8057 Zürich, Switzerland. Phone: 41-43-635-6626; E-mail: stetak{at}zool.unizh.ch and Axel Ullrich, Department of Molecular Biology, Max-Planck-Institute for Biochemistry, Am Klopferspitz 18A, Martinsried, Germany. Phone: 49-89-85782512; Fax: 49-89-85782454; E-mail: ullrich{at}biochem.mpg.de.

Cancer cells often fail to respond to stimuli that normally activate their intrinsic apoptotic machinery. Moreover, they are able to adapt to hypoxia by changing their glycolytic rate. Pyruvate kinase (PK) is a rate-limiting enzyme in glycolysis that is converted to a less active dimer form of PKM2 isoenzyme during oncogenesis. Here, we show that both somatostatin and the structural analogue TT-232 interact with the PKM subtype. We further show that the PKM2 is translocated to the nucleus in response to TT-232 and different apoptotic agents. Nuclear translocation of PKM2 is sufficient to induce cell death that is caspase independent, isoform specific, and independent of its enzymatic activity. These results show that the tumor marker PKM2 plays a general role in caspase-independent cell death of tumor cells and thereby defines this glycolytic enzyme as a novel target for cancer therapy development. [Cancer Res 2007;67(4):1602–8]

This article has been cited by other articles:

				E. Martinez-Balibrea, C. Plasencia, A. Gines, A. Martinez-Cardus, E. Musulen, R. Aguilera, J. L. Manzano, N. Neamati, and A. Abad A proteomic approach links decreased pyruvate kinase M2 expression to oxaliplatin resistance in patients with colorectal cancer and in human cell lines Mol. Cancer Ther., April 1, 2009; 8(4): 771 - 778. [Abstract] [Full Text] [PDF]

				R. Ralhan, L. V. DeSouza, A. Matta, S. Chandra Tripathi, S. Ghanny, S. Datta Gupta, S. Bahadur, and K. W. M. Siu Discovery and Verification of Head-and-neck Cancer Biomarkers by Differential Protein Expression Analysis Using iTRAQ Labeling, Multidimensional Liquid Chromatography, and Tandem Mass Spectrometry Mol. Cell. Proteomics, June 1, 2008; 7(6): 1162 - 1173. [Abstract] [Full Text] [PDF]

				N. Shimada, T. Shinagawa, and S. Ishii Modulation of M2-type pyruvate kinase activity by the cytoplasmic PML tumor suppressor protein. Genes Cells, March 1, 2008; 13(3): 245 - 254. [Abstract] [Full Text] [PDF]